Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

November 08, 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

September 28, 2019

News Conference News VIVA 2016

Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option

October 12, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

September 21, 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

September 20, 2016

News Industry News

REALITY Trial Enrolls First Patient in Study Evaluating Medtronic Directional Atherectomy and Drug-Coated Balloon in PAD Treatment

July 28, 2016

News Industry News

REALITY Study to Evaluate Use of Directional Atherectomy and Drug Coated Balloon in Patients with Peripheral Arterial Disease

November 02, 2015

News Daily News

More Discouraging News for DCBs in Treatment of Infrapopliteal Lesions

October 26, 2015

News Daily News

Más Noticias Desalentadoras para los BRFs en el Tratamiento de Lesiones Infrapoplíteas

October 26, 2015

News Daily News

DCB治疗膝下病变又传出令人失望的消息

October 26, 2015

News Daily News

ZEN Published: Pelvic Artery Stenting Helps Treat Erectile Dysfunction in Some

November 27, 2012

News Daily News

ZEN Publicó: Colocación de stent en la arteria pélvica ayuda a tratar la disfunción eréctil en algunos pacientes

November 27, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.